MedTrace Logo

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

NCT06037889 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 516

Last updated 2026-04-15

No results posted yet for this study

Summary

Branch atheromatous disease (BAD)-related stroke, characterized by subcortical single infarcts without severe stenosis of the large artery, but with a clear atherosclerotic mechanism, is now regarded as a separate stroke type. BAD is associated with early neurological deterioration and poor prognosis, but is lack of effective therapy. The goal of this randomized controlled trial is to test the efficacy and safety of intravenous tirofiban in patients with acute ischemic stroke caused by branch atheromatous disease. The main question it aims to answer is: Compared with standard antiplatelet therapy based on current stroke guideline, whether tirofiban used in acute phase of BAD could improve the proportion of excellent functional outcome (modified Rankin Scale: 0-1) at 90 days. Researcher will also compare the rate of major bleeding between treatment and control groups.

Conditions

  • Branch Atheromatous Disease

Interventions

DRUG

Tirofiban

Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.

DRUG

Aspirin tablet

Aspirin. Oral administration.

DRUG

Clopidogrel tablet

Clopidogrel. Oral administration.

Sponsors & Collaborators

  • Pharmaron (Chengdu) Clinical Services Co., Ltd.

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Jun Ni, MD · The office for BRANT study

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2026-02-26
Completion
2026-02-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06037889 on ClinicalTrials.gov